Advertisement

Multiple Sklerose

  • H. Wiethölter
Chapter
  • 3.7k Downloads

Zusammenfassung

Die multiple Sklerose (MS) ist eine der häufigsten neurologischen Erkrankungen, für deren Ursache es bislang keine einheitliche Erklärung gibt. Grund pfeiler der Diag nostik ist die Klinik, ergänzt durch die Magnetresonanztomographie (MRT). Eine Liquoruntersuchung zum Nachweis der entzündlichen Genese nachgewiesener multifokaler Störungen ist bei allen unklaren Fällen und bei älteren Patienten erforderlich. Zur Bestätigung und Verlaufskontrolle sind elektrophysiologische Verfahren hilfreich.

Die MS verläuft anfangs oft schubförmig-remit tierend, später dann schubförmig- oder sekundär chronisch-progredient. Die kausale Behandlung erfolgt in Abhängigkeit von der Krankheitsaktivität mit Steroiden im akuten Schub und immunmodulatorisch oder immun suppressive entsprechend der vorliegenden Verlaufsform und ihrer Dynamik.

Symptomatische Therapiemaßnahmen tragen ganz wesentlich zur Verbesserung der Lebensqualität und -erwartung bei und werden individuell an die Bedürfnisse angepasst.

Literatur

Zitierte Literatur

  1. Barkhof F, Filipp M, Miller D et al. (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120: 2059–2069CrossRefPubMedGoogle Scholar
  2. Bates D (1994) The diagnosis of multiple sclerosis. Proceedings of the MS forum modern management workshop. Professional Postgraduate Services Europe, Worthing, U.K.Google Scholar
  3. Brønnum-Hansen H, Koch-Hendriksen N, Hyllested K (1994) Survival of patients with multiple sclerosis in Denmark: A nation-wide, long-term epidemiologic survey. Neurology 44: 1901–1907PubMedGoogle Scholar
  4. Bruck W, Stadelmann C (2005) The spectrum of multiple sclerosis: new lessons from pathology. Curr Opin Neurol 18(3): 221–224PubMedGoogle Scholar
  5. Fazekas F, Offenbacher H, Fuchs S et al. (1988) Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 38: 1822–1825PubMedGoogle Scholar
  6. Hardt C (2002) Genetik der Multiplen Sklerose. In: Schmidt RM, Hoffmann F (Hrsg) Multiple Sklerose. Urban & Fischer, München Jena, S 12–18Google Scholar
  7. Hartung HP, Gonsette R, König N et al. (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, mulitcentretrial. Lancet 360: 2018–2025CrossRefPubMedGoogle Scholar
  8. Heckl RW (1994) Multiple Sklerose: Klinik, Differenzialdiagnose, Behandlung. Thieme, Stuttgart New YorkGoogle Scholar
  9. Henze T (2005) Mitoxantron und Immunglobuline. Nervenheilkunde 24: 287–293Google Scholar
  10. Hohlfeld R (1995) Multiple Sklerose. Akt Neurol 22: 125–130Google Scholar
  11. Kesselring J, Ormerod IEC, Miller DH, Boulay EPGH du, McDonald WI (1989) Magnetic resonance imaging in multiple sclerosis — an atlas of diagnosis and differenzial diagnosis. Thieme, StuttgartGoogle Scholar
  12. Krupp LB, Alvarez LA, LaRocca NG et al. (1988) Fatigue in multiple sclerosis. Arch Neurol 45: 435–437PubMedGoogle Scholar
  13. Kurtzke JF (1983) Epidemiology of multiple sclerosis. In: Hallpike JF, Adams CWM, Tourtellotte WW (eds) Multiple sclerosis. Chapman & Hall, London, pp 47–95Google Scholar
  14. McDonald W, Compston A, Edan G et al. (2001) Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121–127CrossRefPubMedGoogle Scholar
  15. Multiple Sklerose Konsensus Gruppe (MSTKG) (2004) Symptomatische Therapie der Multiplen Sklerose. Nervenarzt (Suppl 1) 75: S2–S39Google Scholar
  16. Mumford CJ, Wood NW, Kellar-Wood H (1994) The British isles survey of multiple sclerosis in twins. Neurology 44: 11–15PubMedGoogle Scholar
  17. Paty DW, Li DK, the UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a randomized, double-blind, placebo-controlled trial. Neurology 43: 662–667PubMedGoogle Scholar
  18. Poser S, Wikström J, Bauer HJ et al. (1979) Clinical data and identification of special forms of multiple sclerosis in 1271 cases studied with a standardized documentation system. J Neurol Sci 40: 159–168CrossRefPubMedGoogle Scholar
  19. Poser CM, Paty DW, Scheinberg L et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13: 227–231PubMedGoogle Scholar
  20. Rieckmann P, Kallmann B (2005) Neue Therapieansätze bei Multipler Sklerose. Nervenheilkunde 24: 294–300Google Scholar
  21. Robinson I (1991) The context and consequences of communicating the diagnosis of multiple sclerosis. In: Wiethölter H, Dichgans J, Mertin J (eds) Current Concepts in Multiple Sclerosis. Elsevier, Amsterdam, pp 17–22Google Scholar
  22. Scheglmann K (1995) Multiple Sklerose: Multimodal evozierte Potenziale in der Diagnose. TW Neurol Psychiatr 9: 562–573Google Scholar
  23. Steinbrecher A, Dichgans J, Martin R (1995) Diagnostik und Therapie der multiplen Sklerose. Nervenheilkunde 14: 180–188Google Scholar
  24. Trapp BD, Peterson J, Ransohoff RM et al. (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338(5): 323–325CrossRefGoogle Scholar
  25. Weinshenker BC, Bass R, Rice GPA et al. (1989) The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112: 133–146PubMedGoogle Scholar
  26. Wood DD, Bilbao JM, O’Connors P, Moscarello MA (1996) Acute multiple sclerosis (Marburg type) is associated with developementally immature myelin basic protein. Ann Neurol 40: 18–24CrossRefPubMedGoogle Scholar

Weiterführende Literatur

  1. Betts CD, Jones SJ, Fowler CG, Fowler CJ (1994) Erectile dysfunction in multiple sclerosis; associated neurological and neurophysiological deficits, and treatment of the condition. Brain 117: 1303–1310PubMedGoogle Scholar
  2. Compston A (1999) McAlpine’s Multiple Sclerosis. Churchill Livingstone; London Edinburgh New YorkGoogle Scholar
  3. Giovannoni G, Hartung H-P (1996) The immunopathogenesis of multiple sclerosis and Guillain-Barré syndrome. Curr Op Neurol 9: 165–177Google Scholar
  4. Kesselring J (1997) Multiple Sklerose. Kohlhammer, Stuttgart Berlin KölnGoogle Scholar
  5. Leary SM, Thompson AJ (2005) Primary progressive multiple sclerosis: current and future treatment options. CNS Drugs 19(5): 369–376CrossRefPubMedGoogle Scholar
  6. Matthews WB (ed) (1991) McAlpine’s Multiple Sclerosis. Churchill Livingstone, EdinburghGoogle Scholar
  7. McFarland HF, Frand JA, Albert PS et al. (1992) Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 32: 758–766PubMedGoogle Scholar
  8. Moulin DE (1989) Pain in multiple sclerosis. Neurol Clin 7: 321–331PubMedGoogle Scholar
  9. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) (2004) Escalating immunotherapy of multiple sclerosis — New aspects and practical application. J Neurol 251: 1329–1339Google Scholar
  10. Poser S (1996) Diagnose. In: Poser S (Hrsg) Taschenbuch Multiple Sklerose. Blackwell, Berlin Wien, S 53–87Google Scholar
  11. Seidel D (1995) Multiple Sklerose — Symptomatische Therapie und Rehabilitation. TW Neurol Psychiatr 9: 574–582Google Scholar
  12. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655–661Google Scholar
  13. Wiethölter H (2005) Schubprophylaxe mi Interferonen und Glatiramerazetat. Nervenheilkunde 24: 279–286Google Scholar

Copyright information

© Springer Medizin Verlag Heidelberg 2006

Authors and Affiliations

  • H. Wiethölter
    • 1
  1. 1.Bürgerhospital, Neurologische KlinikStuttgart

Personalised recommendations